Edition:
United Kingdom

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

7.08USD
19 Jul 2018
Change (% chg)

$-0.13 (-1.80%)
Prev Close
$7.21
Open
$7.20
Day's High
$7.30
Day's Low
$6.93
Volume
102,764
Avg. Vol
226,847
52-wk High
$8.40
52-wk Low
$0.95

Chart for

About

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $113.17
Shares Outstanding(Mil.): 60.20
Dividend: --
Yield (%): --

Financials

  CASI.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -0.13 -- --
ROI: -45.17 2.21 14.61
ROE: -62.67 3.85 16.34

BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26

* CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE

05 Apr 2018

BRIEF-CASI Pharmaceuticals Q4 Loss Per Share $0.08

* CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

29 Mar 2018

BRIEF-CASI Pharmaceuticals Announces $50 Million Private Placement

* CASI PHARMACEUTICALS ANNOUNCES $50 MILLION PRIVATE PLACEMENT TO PREPARE COMPANY FOR COMMERCIALIZATION IN CHINA

20 Mar 2018

BRIEF-Casi Pharmaceuticals Enters Into A Common Stock Sales Agreement With H.C. Wainwright & Co

* CASI PHARMACEUTICALS INC SAYS ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO LLC - SEC FILING

23 Feb 2018

BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman

* CASI PHARMACEUTICALS - ON FEB 7, BOARD APPROVED APPOINTMENT OF WEI-WU HE, CURRENT CHAIRMAN OF BOARD, AS EXECUTIVE CHAIRMAN - SEC FILING Source text: (http://bit.ly/2EUtR7g) Further company coverage:

09 Feb 2018

Competitors

Earnings vs. Estimates